
========================================================================================
CASE: Imatinib for chronic myeloid leukemia
QUERY: Assess imatinib (ChEMBL CHEMBL941) as a therapy for chronic myeloid leukemia (ICD C92), focusing on its canonical target ABL1. Consider LinkD's predicted binding to ABL1, the drug's selectivity, any real-world EHR association, and the overall multi-evidence score. Then give a recommendation.
----------------------------------------------------------------------------------------
  [tool 1] linkd_binding(drug_chembl=CHEMBL941, gene=ABL1)
           -> {"query": {"drug": "CHEMBL941", "gene": "ABL1"}, "result": {"drug_id": "CHEMBL941", "target": "ABL1_HUMAN", "binding_affinity": 8.904458999633789, "selectivity_
  [tool 2] linkd_selectivity(drug_chembl=CHEMBL941)
           -> {"query": {"drug": "CHEMBL941", "name": ""}, "found": true, "drug": {"Drug": "CHEMBL941", "Drug Name": "Imatinib", "Selectivity_Score": 0.3535525384637464, "n_t
  [tool 3] linkd_ehr(drug_name=imatinib, icd=C92)
           -> {"query": {"drug": "", "name": "imatinib", "icd": "C92", "disease": ""}, "count": 0, "rows": []}
  [tool 4] linkd_evidence(drug_chembl=CHEMBL941, gene=ABL1, icd=C92)
           -> {"drug_id": "CHEMBL941", "gene": "ABL1", "disease": "C92", "sources": {"binding_affinity": {"found": true, "pkd": 8.904458999633789, "selectivity_score": 0.5193

  VERDICT (gpt-5.4, 4 tool calls):
  **Assessment: imatinib (CHEMBL941) for chronic myeloid leukemia, focusing on ABL1**
  
  ### Key LinkD findings
  - **Predicted binding to ABL1:** **pKd 8.90**
    - This is strong predicted affinity and is very consistent with imatinib’s known canonical mechanism as an **ABL1 tyrosine kinase inhibitor**.
  - **Selectivity:** **0.354**, labeled **“Type II: Moderate poly-target”**
    - This fits biology well: imatinib is **not ultra-selective**; it also hits kinases such as KIT and PDGFR family members. I would treat this as **moderately selective**, not highly selective.
  - **Real-world EHR association for imatinib–C92:** **no rows found**
    - This is **weak/no evidence**, not negative evidence. For a cancer like CML, EHR association analyses can be sparse or hard to interpret because of indication bias and small usable cohorts.
  - **Overall multi-evidence score for imatinib–ABL1–C92:** **0.6947**, verdict **“strong”**
    - Supporting components include:
      - predicted binding sub-score **0.817**
      - CRISPR/drug-response sub-score **0.949**
      - target-priority sub-score **0.844**
      - coverage **0.86**
  
  ### Interpretation
  This is a **strong positive case**. The most important evidence is:
  1. **Strong ABL1 binding (pKd 8.90)**
  2. **Strong overall triad score (0.6947; “strong”)**
  3. **High functional support from drug-response/CRISPR correlation (0.949)**
  
  The only relative limitation is **modest selectivity** (**0.354**), but for imatinib that is expected and not disqualifying. In fact, this aligns with established pharmacology rather than raising a red flag.
  
  The **lack of EHR signal** should not count much against the drug here, because the result is simply absent rather than statistically negative, and observational EHR analyses are often weak for oncology efficacy questions.
  
  ### Recommendation
  **Recommend imatinib as a strong therapy candidate for CML (C92) via ABL1 inhibition.**  
  On LinkD evidence, it looks **well-supported**, with strong predicted ABL1 engagement and a strong aggregated score despite only moderate kinase selectivity and no informative EHR readout.
  
  ### Concise verdict
  - **Recommendation:** **Strongly support**
  - **Main drivers:**  
    - **ABL1 pKd = 8.90**  
    - **Multi-evidence final_score = 0.6947 (“strong”)**  
    - **Functional/CRISPR sub-score = 0.949**
  - **Override of LinkD:** none needed; the moderate selectivity call is biologically plausible, and the missing EHR result is appropriately treated as weak/non-informative rather than contradictory evidence.

========================================================================================
CASE: Erlotinib mechanism + EGFR support in lung cancer
QUERY: What is the mechanism of erlotinib (ChEMBL CHEMBL553) — is it a selective EGFR inhibitor? Check LinkD's top binding targets and selectivity, then how strong the multi-evidence support is for EGFR in non-small-cell lung carcinoma (ICD C34). Cross-check LinkD against what you know.
----------------------------------------------------------------------------------------
  [tool 1] linkd_targets_for_drug(drug_chembl=CHEMBL553)
           -> {"query": {"drug": "CHEMBL553"}, "count": 15, "targets": [{"Drug": "CHEMBL553", "Target": "EGFR_HUMAN", "aff_local": 9.50910758972168, "Selectivity_Score": 0.62
  [tool 2] linkd_selectivity(drug_chembl=CHEMBL553)
           -> {"query": {"drug": "CHEMBL553", "name": ""}, "found": true, "drug": {"Drug": "CHEMBL553", "Drug Name": "Erlotinib", "Selectivity_Score": 0.3300718419239333, "n_
  [tool 3] linkd_binding(drug_chembl=CHEMBL553, gene=EGFR)
           -> {"query": {"drug": "CHEMBL553", "gene": "EGFR"}, "result": {"drug_id": "CHEMBL553", "target": "EGFR_HUMAN", "binding_affinity": 9.50910758972168, "selectivity_s
  [tool 4] linkd_evidence(drug_chembl=CHEMBL553, gene=EGFR, icd=C34)
           -> {"drug_id": "CHEMBL553", "gene": "EGFR", "disease": "C34", "sources": {"binding_affinity": {"found": true, "pkd": 9.50910758972168, "selectivity_score": 0.62041
  [tool 5] linkd_targets_for_disease(icd=C34)
           -> {"query": {"disease": "", "icd": "C34"}, "count": 479, "ranked_genes": ["EGFR", "KDR", "TUBB", "TUBB1", "TUBB2A", "TUBB2B", "TUBB3", "TUBB4A", "TUBB4B", "TUBB6"

  VERDICT (gpt-5.4, 5 tool calls):
  LinkD supports erlotinib as an EGFR-directed drug, but its own target list does not make it look cleanly EGFR-only. My view: erlotinib is best described as a clinically established, relatively selective EGFR tyrosine kinase inhibitor, with some plausible off-target kinase activity; I would not call it exquisitely selective based on the LinkD target panel alone.
  
  What LinkD says
  
  - Top predicted binding targets for CHEMBL553:
    - EGFR pKd 9.51
    - CHK1 pKd 9.29
    - IRAK3 pKd 9.08
    - KIT pKd 9.04
    - BRAF pKd 9.03
    - then several other kinases around pKd 8.6–8.9
  - Direct EGFR binding query:
    - EGFR pKd = 9.51
    - target-level selectivity score = 0.620
    - rank_select = 6
  - Drug-level selectivity:
    - Selectivity_Score = 0.330
    - drug_type = “Type I: Highly Selective”
    - measured across 20,385 targets
  - Disease target ranking for NSCLC / C34:
    - EGFR is ranked #1 for C34 in LinkD
  - Multi-evidence for erlotinib–EGFR–C34:
    - final_score = 0.6981
    - verdict = strong
    - strength_score = 0.7507
    - coverage = 0.86
    - key sub-scores:
      - predicted_binding = 0.918
      - functional_crispr/drug_response = 0.912
      - target_priority = 0.831
      - clinical_phase = 0.75
      - genetic_causality = 0.6
      - drug_selectivity = 0.330
    - EHR evidence missing
  
  Cross-check against known pharmacology
  
  - This broadly matches established knowledge: erlotinib is a first-generation reversible EGFR TKI used in EGFR-mutant non-small-cell lung cancer.
  - It is generally considered EGFR-focused clinically, though not perfectly selective in the absolute kinome sense.
  - The LinkD binding list showing CHK1, IRAK3, KIT, and BRAF almost as strong as EGFR is more promiscuous than I would expect from canonical pharmacology. I would treat those as hypothesis-generating predictions, not enough to overturn the well-established EGFR mechanism.
  - So I would partially override the implication of the raw top-target list if interpreted literally: EGFR should still be regarded as the primary mechanism-of-action target.
  
  Bottom line
  
  - Mechanism: Erlotinib is an EGFR tyrosine kinase inhibitor.
  - Is it selective? Yes, selective enough that EGFR is the primary target/mechanism, but not obviously EGFR-exclusive from LinkD’s predicted binding panel.
  - Support for EGFR in NSCLC (C34): strong.
  
  Structured verdict
  
  - Recommendation: Treat erlotinib as a bona fide EGFR inhibitor for NSCLC, with strong support for the EGFR–C34 mechanism.
  - Main LinkD drivers:
    1. EGFR is the top predicted binding target with pKd 9.51.
    2. EGFR is the #1 ranked disease target for C34.
    3. EGFR/C34 multi-evidence final_score 0.6981, verdict “strong”.
  - Override of LinkD:
    - I would not over-interpret the near-equal predicted binding to CHK1/IRAK3/KIT/BRAF; known biology supports EGFR as the dominant clinically relevant target of erlotinib.

========================================================================================
CASE: Melanoma — disease-first target triage
QUERY: For melanoma (ICD C43), what are LinkD's top drug-target genes? Pick the most actionable one, check the predicted binding of vemurafenib (ChEMBL CHEMBL1229517) to it and the multi-evidence score, and recommend whether it is a strong target.
----------------------------------------------------------------------------------------
  [tool 1] linkd_targets_for_disease(icd=C43)
           -> {"query": {"disease": "", "icd": "C43"}, "count": 180, "ranked_genes": ["KDR", "KIT", "PDGFRB", "FLT1", "FLT4", "BRAF", "MAP2K1", "MAP2K2", "PDCD1", "TUBB", "TU
  [tool 2] linkd_binding(drug_chembl=CHEMBL1229517, gene=BRAF)
           -> {"query": {"drug": "CHEMBL1229517", "gene": "BRAF"}, "result": {"drug_id": "CHEMBL1229517", "target": "BRAF_HUMAN", "binding_affinity": 6.777839183807373, "sele
  [tool 3] linkd_evidence(drug_chembl=CHEMBL1229517, gene=BRAF, icd=C43)
           -> {"drug_id": "CHEMBL1229517", "gene": "BRAF", "disease": "C43", "sources": {"binding_affinity": {"found": true, "pkd": 6.777839183807373, "selectivity_score": 0.
  [tool 4] linkd_binding(drug_chembl=CHEMBL1229517, gene=KIT)
           -> {"query": {"drug": "CHEMBL1229517", "gene": "KIT"}, "result": {"drug_id": "CHEMBL1229517", "target": "KIT_HUMAN", "binding_affinity": 7.382368564605713, "select
  [tool 5] linkd_evidence(drug_chembl=CHEMBL1229517, gene=KIT, icd=C43)
           -> {"drug_id": "CHEMBL1229517", "gene": "KIT", "disease": "C43", "sources": {"binding_affinity": {"found": true, "pkd": 7.382368564605713, "selectivity_score": 0.5
  [tool 6] linkd_binding(drug_chembl=CHEMBL1229517, gene=KDR)
           -> {"query": {"drug": "CHEMBL1229517", "gene": "KDR"}, "result": {"drug_id": "CHEMBL1229517", "target": "VGFR2_HUMAN", "binding_affinity": 5.753951549530029, "sele
  [tool 7] linkd_evidence(drug_chembl=CHEMBL1229517, gene=KDR, icd=C43)
           -> {"drug_id": "CHEMBL1229517", "gene": "KDR", "disease": "C43", "sources": {"binding_affinity": {"found": true, "pkd": 5.753951549530029, "selectivity_score": 0.3
  [tool 8] linkd_selectivity(drug_chembl=CHEMBL1229517)
           -> {"query": {"drug": "CHEMBL1229517", "name": ""}, "found": true, "drug": {"Drug": "CHEMBL1229517", "Drug Name": "Vemurafenib", "Selectivity_Score": 0.17700661264
  [tool 9] linkd_targets_for_drug(drug_chembl=CHEMBL1229517)
           -> {"query": {"drug": "CHEMBL1229517"}, "count": 15, "targets": [{"Drug": "CHEMBL1229517", "Target": "GNRHR_HUMAN", "aff_local": 7.638608455657959, "Selectivity_Sc

  VERDICT (gpt-5.4, 9 tool calls):
  For melanoma (ICD C43), LinkD’s top disease-ranked target genes are:
  
  - KDR
  - KIT
  - PDGFRB
  - FLT1
  - FLT4
  - BRAF
  - MAP2K1
  - MAP2K2
  - PDCD1
  - TUBB family genes
  
  Most actionable one: BRAF
  
  Why BRAF over the higher-ranked angiogenesis genes:
  - It is the canonical, clinically validated melanoma driver target.
  - Vemurafenib is a known BRAF-directed melanoma drug.
  - LinkD gives BRAF strong disease-drug-target support with functional and clinical backing.
  - I am overriding the raw disease rank here: LinkD ranks KDR/KIT above BRAF for C43, but for vemurafenib specifically, BRAF is the more actionable and biologically credible target in melanoma.
  
  Vemurafenib → BRAF:
  - Predicted binding affinity (pKd): 6.78
  - Multi-evidence final_score: 0.6373
  - LinkD verdict: strong
  
  Cross-checks:
  - BRAF triad has CRISPR/drug-response support: best AUC correlation 0.353, FDR 2.98e-14
  - Clinical phase support is maximal: phase 4
  - Melanoma genetic causality is present for BRAF
  - Drug-level selectivity is reported as highly selective, though the per-target binding ranking looks imperfect, so I trust the triad evidence more than the raw global target list
  
  Recommendation:
  - Yes — BRAF is a strong target for melanoma for vemurafenib.
  
  Key LinkD numbers driving this:
  1. BRAF final_score in melanoma: 0.6373, verdict strong
  2. Vemurafenib–BRAF predicted binding pKd: 6.78
  3. Functional support: CRISPR/drug-response correlation 0.353, FDR 2.98e-14
  
  Override noted:
  - I overrode LinkD’s disease-only rank ordering (KDR/KIT above BRAF) because for vemurafenib in melanoma, BRAF is the most actionable and best-validated target.
